Abstract
Cancer stem-like cells (CSC) play key roles in long-term tumor propagation and metastasis, but their dynamics during disease progression are not understood. Tumor relapse in patients with initially excised skin squamous cell carcinomas (SCC) is characterized by increased metastatic potential, and SCC progression is associated with an expansion of CSC. Here, we used genetically and chemically-induced mouse models of skin SCC to investigate the signaling pathways contributing to CSC function during disease progression. We found that CSC regulatory mechanisms change in advanced SCC, correlating with aggressive tumor growth and enhanced metastasis. β-Catenin and EGFR signaling, induced in early SCC CSC, were downregulated in advanced SCC. Instead, autocrine FGFR1 and PDGFRα signaling, which have not been previously associated with skin SCC CSC, were upregulated in late CSC and promoted tumor growth and metastasis, respectively. Finally, high-grade and recurrent human skin SCC recapitulated the signaling changes observed in advanced mouse SCC. Collectively, our findings suggest a stage-specific switch in CSC regulation during disease progression that could be therapeutically exploited by targeting the PDGFR and FGFR1 pathways to block relapse and metastasis of advanced human skin SCC.
Highlights
Skin squamous cell carcinoma (SCC) is the second most common nonmelanoma skin cancer in humans
To determine whether the aggressive growth and enhanced metastasis of advanced SCCs are associated with changes in Cancer stem-like cells (CSC) features, we generated mouse models of skin SCC progression based on tumors developed in K14-HPV16 mice
After serial engraftments, 62.5% of the WD-SCCs showing epithelial differentiation features progressed to moderated SCCs (MD-SCC), which evolved to PD-SCCs that frequently contained focal spindle regions, and to mesenchymal-shaped spindle tumors, in which the epithelial phenotype was completely lost (Supplementary Fig. S1A; Supplementary Table S1)
Summary
Skin squamous cell carcinoma (SCC) is the second most common nonmelanoma skin cancer in humans. Eight percent to 10% of patients suffer tumor relapse after surgical excision, which is associated with an enhanced propensity to metastasize and with poor survival [1]. SCC development in humans and mice is a multistage process ending in the generation of invasive tumors [2]. Most invasive tumors conserve some epithelial traits and are considered to be well-differentiated. Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.